IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication
- PMID: 20567020
- DOI: 10.1200/JCO.2010.28.3762
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication
Abstract
Purpose: To analyze the frequency and prognostic impact of isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) mutations in acute myeloid leukemia (AML).
Patients and methods: We studied 805 adults (age range, 16 to 60 years) with AML enrolled on German-Austrian AML Study Group (AMLSG) treatment trials AML HD98A and APL HD95 for mutations in exon 4 of IDH1 and IDH2. Patients were also studied for NPM1, FLT3, MLL, and CEBPA mutations. The median follow-up for survival was 6.3 years.
Results: IDH mutations were found in 129 patients (16.0%) -IDH1 in 61 patients (7.6%), and IDH2 in 70 patients (8.7%). Two patients had both IDH1 and IDH2 mutations. All but one IDH1 mutation caused substitutions of residue R132; IDH2 mutations caused changes of R140 (n = 48) or R172 (n = 22). IDH mutations were associated with older age (P < .001; effect conferred by IDH2 only); lower WBC (P = .04); higher platelets (P < .001); cytogenetically normal (CN) -AML (P< .001); and NPM1 mutations, in particular with the genotype of mutated NPM1 without FLT3 internal tandem duplication (ITD; P < .001). In patients with CN-AML with the latter genotype, IDH mutations adversely impacted relapse-free survival (RFS; P = .02) and overall survival (P = .03), whereas outcome was not affected in patients with CN-AML who lacked this genotype. In CN-AML, multivariable analyses revealed a significant interaction between IDH mutation and the genotype of mutated NPM1 without FLT3-ITD (ie, the adverse impact of IDH mutation [RFS]; P = .046 was restricted to this patient subset).
Conclusion: IDH1 and IDH2 mutations are recurring genetic changes in AML. They constitute a poor prognostic factor in CN-AML with mutated NPM1 without FLT3-ITD, which allows refined risk stratification of this AML subset.
Similar articles
-
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368543 Free PMC article.
-
[Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].Zhonghua Xue Ye Xue Za Zhi. 2012 May;33(5):397-401. Zhonghua Xue Ye Xue Za Zhi. 2012. PMID: 22781800 Chinese.
-
[Mutation of isocitrate dehydrogenase 2 (IDH2) gene in Chinese AML patients and its clinical significance].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Jun;21(3):607-12. doi: 10.7534/j.issn.1009-2137.2013.03.014. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013. PMID: 23815907 Chinese.
-
Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.Ann Hematol. 2014 Aug;93(8):1279-86. doi: 10.1007/s00277-014-2072-6. Epub 2014 May 7. Ann Hematol. 2014. PMID: 24801015 Review.
-
IDH mutations in acute myeloid leukemia.Hum Pathol. 2012 Oct;43(10):1541-51. doi: 10.1016/j.humpath.2012.05.003. Epub 2012 Aug 20. Hum Pathol. 2012. PMID: 22917530 Review.
Cited by
-
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.Leukemia. 2024 May;38(5):927-935. doi: 10.1038/s41375-024-02246-2. Epub 2024 Apr 10. Leukemia. 2024. PMID: 38600315 Free PMC article. Review.
-
Novel Therapeutic Targets in Acute Myeloid Leukemia (AML).Curr Oncol Rep. 2024 Apr;26(4):409-420. doi: 10.1007/s11912-024-01503-y. Epub 2024 Mar 19. Curr Oncol Rep. 2024. PMID: 38502417 Free PMC article. Review.
-
IDALLO study: A retrospective multicenter study of the SFGM-TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1-mutated AML after allogeneic hematopoietic cell transplantation.Hemasphere. 2024 Mar 10;8(3):e44. doi: 10.1002/hem3.44. eCollection 2024 Mar. Hemasphere. 2024. PMID: 38469458 Free PMC article. No abstract available.
-
p32 regulates glycometabolism and TCA cycle to inhibit ccRCC progression via copper-induced DLAT lipoylation oligomerization.Int J Biol Sci. 2024 Jan 1;20(2):516-536. doi: 10.7150/ijbs.84399. eCollection 2024. Int J Biol Sci. 2024. PMID: 38169635 Free PMC article.
-
A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML.Blood Adv. 2024 Feb 13;8(3):629-639. doi: 10.1182/bloodadvances.2023011219. Blood Adv. 2024. PMID: 38029373 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous